Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study.
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis.
Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Clinical Characteristics of Pediatric-Onset and Adult-Onset Multiple Sclerosis in Hispanic Americans.
Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis.
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner.
Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
Pharmacokinetics and metabolism of mitoxantrone. A review.
Time to wake up and smell the coffee? Coffee consumption and multiple sclerosis.
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis.
Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
Avonex approval application
Synthetic Biologics announces issuance of U.S. patent covering combination of estriol and Copaxone® for multiple sclerosis
Dimethylfumarate Impairs Neutrophil Functions.
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis.
Covis Pharma to Acquire U.S. Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®
The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform.
Aubagio® significantly reduced risk of new clinical relapse or MRI lesion in multiple sclerosis study

Pages